Kahlil's questions to Cytokinetics Inc (CYTK) leadership • Q4 2024
Question
An analyst identified as Kahlil asked about the potential timeline for a label expansion for aficamten following positive results from the MAPLE-HCM trial and how those results would be incorporated into the marketing strategy.
Answer
EVP of R&D Fady Malik stated that a label expansion would likely occur in 2026, contingent on the PDUFA date and other factors. EVP & CCO Andrew Callos explained that positive MAPLE-HCM data would provide confirmatory evidence, potentially opening up the market to cardiologists who currently only use beta-blockers and influencing treatment guidelines over time. President & CEO Robert I. Blum added that it could drive incremental category growth and increase aficamten's penetration.